March 2017 | Volume 2

From our conversations with device companies, investors and surgeons, it's become clear that companies that capitalize on one of these three aspects of care will be best positioned to maintain or grow their share of the joint reconstruction market.
NuVasive is ahead of schedule in hiring 300 people at its manufacturing facilities in Ohio, according to local press. The company had hired nearly 150 employees in early February 2017, and is expected to fill all remaining positions by the end of the year.

Last week, we received a call from a reader who said he'd spoken to colleagues at eight orthopaedic device companies, large and small. They'd failed the clinical evaluation portion of the initial CE Mark or audit process. 

Many medical implant products and instruments require UT evaluation to assure that the component is free from defects.
Revenue from orthopaedics' five largest players (DePuy Synthes, Zimmer Biomet, Stryker, Smith & Nephew and Medtronic) grew by $671.7 million in 2016, up 2.4% from 2015, to reach $28.6 billion.

Study results indicate that percutaneous intramedullary fixation, such as that provided by the IlluminOss system, can provide stabilization of long bone fractures without open surgery.
DePuy Synthes Mitek Sports Medicine launched a suite of knee arthroscopy implants and instruments for anterior cruciate ligament and meniscus repair.